Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of PF-07293893 in Healthy Adults
NCT06177457Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of PF-07293893 in heart failure with preserved ejection fraction (HFpEF) (9 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) at 11 weeks, Number of Participants With Clinical Laboratory Abnormalities at 7 weeks and 6 more. Started Dec 2023; status: completed.
02
Drugs
PF-07293893
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06177457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06177457.